Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07020221 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Verastem.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 295
- Enrollment target
- 12
- Study locations
NCT07020221: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Verastem.
NCT07020221 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is actively recruiting participants, run by Verastem. The registered enrollment target is 295 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (55% lower). The trial reports 12 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07020221, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Verastem.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 295 participants
- Enrollment target
- 12
- Study locations
Study Summary
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Primary Outcome
To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375 administered on a daily oral schedule in participants with advanced solid tumors harboring a KRAS G12D mutation. Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, DLTs, and dose interruptions/reductions.
Conditions Studied
Interventions
- DRUG Cetuximab
- DRUG Gemcitabine
- DRUG VS-7375
- DRUG Carboplatin + Pemetrexed + Pembrolizumab
- DRUG Gemcitabine + Nab-paclitaxel
Study Locations (12)
California
- Cedars-Sinai Medical Center - Los Angeles
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan - Ann Arbor
Missouri
- Washington University School of Medicine - St Louis
New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone - New York
Pennsylvania
- Univ of Pennsylvania, Abramson Cancer Center - Philadelphia
Tennessee
- SCRI Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2025-06-24 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT07020221 shows while recruiting
NCT07020221 is an interventional study that assigns participants to a tested intervention. The registered 295 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (55% lower).
The record links to 5 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Cetuximab is the first listed.
NCT07020221 lists 12 locations in 12 states (California, Maryland, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT07020221 about?
NCT07020221 is a clinical study titled "A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors". This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
What is the current status of trial NCT07020221?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 295 participants. The study started on 2025-06-24. Estimated completion is 2028-12.
What conditions does trial NCT07020221 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor, Adult, G12D Mutated KRAS.
What interventions are being tested in trial NCT07020221?
The interventions under investigation include: Cetuximab (DRUG), Gemcitabine (DRUG), VS-7375 (DRUG), Carboplatin + Pemetrexed + Pembrolizumab (DRUG), Gemcitabine + Nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT07020221?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07020221 being conducted?
This trial has 12 study locations across California, Maryland, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07020221's enrollment target sits among peer trials
295 128th of 454 higher than 327 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05201781 · 295 participants · Phase 4
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- NCT06004245 · 295 participants · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- NCT06494111 · 295 participants · Phase 2
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
- NCT05563792 · 296 participants · NA
Options for Pain Management Using Nonpharmacological Strategies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI